CLINICAL BENEFITS

Precision Pairing at the Genetic Level

Using the most popular medications for all patients often falls short of the desired outcomes. Unlike other tests that focus solely on mental health, Mira Precision PGx offers a comprehensive pharmacogenomics (PGx) test that provides personalized medication profiles across 12 therapeutic areas, tailored to a patient’s unique DNA. This advanced test considers more factors influencing medication response than any other PGx test available.

Precision Prescribing for Personalized Patient Care in
Internal Medicine & Family Practice

Using one-size-fits-all medications often falls short of achieving desired outcomes. Mira Precision PGx delivers a comprehensive, personalized medication profile across 12 therapeutic areas, tailored to each patient’s unique DNA. Unlike tests focused solely on mental health, this advanced PGx test considers more factors influencing medication response than any other available—bringing improved accuracy, reduced adverse drug reactions, and cost-effective care to every patient.

Personalized Treatment Strategies

PGx testing tailors medication regimens, improving efficacy and minimizing trial-and-error. Up to 50% of patients may not respond to initial antidepressant therapy due to genetic factors, and the CPIC recommends PGx-guided treatment for over 60 medications.

Reduction in Adverse Drug Reactions (ADRs)

ADRs cause over 1.5 million preventable incidents annually in the U.S., leading to ER visits and hospitalizations. PGx testing enables medication adjustments based on genetics, reducing ADR risks—particularly for high-risk drugs like opioids.

Cost Savings & Treatment Optimization

ADRs contribute to about $3.5 billion in excess healthcare costs annually. PGx testing ensures appropriate medication selection, reduces ineffective treatments, and minimizes costs from hospital admissions and medication misuse.

Elevated Quality of Care Through Decision Support

PGx testing tailors medication regimens, improving efficacy and minimizing trial-and-error. Up to 50% of patients may not respond to initial antidepressant therapy due to genetic factors, and the CPIC recommends PGx-guided treatment for over 60 medications.

Improved Patient Outcomes and Adherence

A cost-effectiveness study found that PGx testing saved up to $4,000 per patient annually for high-risk populations, such as patients with cardiovascular disease or chronic pain, by optimizing medication regimens.

Reduction in Hospitalization and ER Visits

The NIH reports that PGx testing for patients on polypharmacy led to a 40% reduction in hospitalizations and 70% fewer ER visits due to ADRs.

Cost-Effectiveness in High-Risk Populations

A study on PGx-guided prescribing for antidepressants and antipsychotics showed a 70% improvement in remission rates, highlighting PGx testing’s potential to enhance mental health outcomes.

  1. Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014;95(4):423-431.
  2. Yuan, J., et al. Preemptive Pharmacogenomic Testing for Precision Medicine. J Mol Diag. 2016;18(3):438-445.
  3. U.S. Food & Drug Administration. Table of Pharmacogenetic Associations FDA.gov.
  4. Mayo Clinic Proceedings. (2015). Clinical Implementation of Cardiovascular Pharmacogenomics. Mayo Clinic Proceedings.
  5. Schildcrout J.S., Denny J.C., Bowton E., et al. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clin Pharmacol Ther. 2012;92:235–242. doi: 10.1038/clpt.2012.66.
  6. Kimpton J., Carey I.M., Threapleton C.J., et al. Longitudinal exposure of English primary care patients to pharmacogenomic drugs: An analysis to inform design of pre-emptive pharmacogenomic testing. Br J Clin Pharmacol. 2019;85:2734–2746. doi: 10.1111/bcp.14100.
  7. Bradley, P., et al. (2018). Effectiveness of Pharmacogenomic Testing for the Treatment of Major Depressive Disorder in a Primary Care Setting. Journal of Psychiatric Research.
  8. National Institutes of Health (NIH). Pharmacogenomics: Precision Medicine and Patient Outcomes. NIH.gov.
  9. Bentley, T. G., et al. (2017). Cost-Effectiveness of Pharmacogenomic Testing in Patients with Chronic Pain and Cardiovascular Disease. Health Economic

Unlock the Power of Mira Precision PGx

PGx testing reveals a person’s metabolic phenotype, showing how their genes affect drug metabolism. Some individuals metabolize medications rapidly due to specific genetic variations, requiring higher doses for effectiveness and fewer side effects. Mira Precision PGx ensures that each patient receives the most suitable treatment, tailored precisely to their genetic makeup, whether it’s for oncology, cardiology, psychiatry, neurology, gastroenterology, endocrinology, rheumatology, respiratory, infectious diseases, pain management, urology, dermatology, or hematology.

Drug-Gene Interaction

Drug-Drug Interactions

Lifestyle factors & Environment

Integrating Mira Precision PGx into Long-Term
Care (LTC) Facilities

By integrating PGx testing:

LTC facilities can improve their medication management, reduce ADRs, and enhance overall care quality, all of which contribute to achieving high CMS Star Ratings and reaping the associated rewards.

Ordering Mira Precision PGx

Order Test